Ambrisentan

Type: Keyphrase
Name: Ambrisentan
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Lung Diseases and Conditions: New Data from Department of Cardiology Illuminate Findings in Pulmonary Hypertension

Today's Medical & Research NewsLung Diseases and Conditions2014 APR 17 -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on Lung Diseases and Conditions have been presented. According to news reporting from Foggia, Italy, ... [Published NewsRX - Apr 17 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Management of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a life-limiting, incurable condition. Recent guidance from NICE identifies priorities of care for this group of patientsIn this article… Definition of idiopathic pulmonary fibrosis Priorities for managing patients with ... [Published Nursing Times - Apr 11 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Methods of treating mixed dyslipidemia

Description of the InventionBACKGROUNDCardiovascular disease is one of the leading causes of death in the United States and most European countries. It is estimated that over 70 million people in the United States alone suffer from a cardiovascular disease ... [Published PharmCast - Apr 08 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Contrary to popular belief, side-effect reports on new meds keep a steady pace, study finds

AdverseEvents CEO Brian Overstreet--Courtesy of AdverseEventsSide-effect reports to the FDA are a contentious subject. Despite a series of efforts to improve adverse-event reporting, numbers from the agency's database tend to be quoted with an accompanying ... [Published FiercePharma - Mar 19 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Bone Metabolism Biomarkers Predict Prostate Cancer Survival

Levels of biomarkers linked to bone metabolism (bone formation and resorption) are indicative of survival in patients with castration-resistant prostate cancer (CRPC), and identify a small group of patients who can benefit from treatment with the investigational ... [Published Lab Medica - Mar 19 2014]

Quotes

The news correspondents obtained a quote from the research from the Department of Cardiology, "Interferon-gamma-1b showed a significant improvement in pulmonary function only in one study. Pirfenidone, cyclosporine and acetylcysteine may also be of benefit but data from studies are limited. Novel drugs, mainly antifibrotic, anticytokine and immunoregulatory, are currently being investigated in various trial phases. Endothelin receptor antagonists have been shown to have possible beneficial effects in early stages of IPF. However, most recently, the so-called triple combination therapy, anticoagulation therapy and endothelin receptor antagonists, especially ambrisentan, are either harmful or ineffective in IPF and are not recommended."
...as gospel," said Overstreet, who's also CEO of AdverseEvents, a company that analyzes FAERS for payers, healthcare systems and pharma companies. "It's been accepted as dogma that the data can't be used."
...Primo Lara, associate director for translational research at the University of California Davis. "By measuring bone turnover in prostate cancer patients, we can determine how well they do."

More Content

All (6) | News (5) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Lung Diseases and Conditions: New Data from Dep... [Published NewsRX - Apr 17 2014]
Management of idiopathic pulmonary fibrosis [Published Nursing Times - Apr 11 2014]
Methods of treating mixed dyslipidemia [Published PharmCast - Apr 08 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Mar 27 2014]
Contrary to popular belief, side-effect reports... [Published FiercePharma - Mar 19 2014]
Bone Metabolism Biomarkers Predict Prostate Can... [Published Lab Medica - Mar 19 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Mar 27 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.